Lisata Acquires Marea in $225M Cardioendocrine Deal
LIBERTY CORNER, N.J. — September 17, 2026 Lisata Therapeutics announced the acquisition of Marea Therapeutics, combining the companies to...
acromegaly
Advertisement
DelveInsight: CABP Market Set for Growth Through 2036
Las Vegas, Nevada, USA, September 7, 2026 The community-acquired bacterial pneumonia (CABP) treatment market is expected to expand through...
FDA Acts to Protect Access to Newborn Nutrition Products
Silver Spring, Maryland, USA, September 5, 2026 The U.S. Food and Drug Administration (FDA) has announced steps intended to...
Vertex Completes Crinetics Acquisition in $10 Billion Deal
Boston, Massachusetts, USA, September 1, 2026 Vertex Pharmaceuticals Incorporated has completed its acquisition of Crinetics Pharmaceuticals, Inc., strengthening its...
Camurus NDA Resubmission for CAM2029 Accepted by FDA
LUND, Sweden, July 17, 2026 Camurus announced that the U.S. Food and Drug Administration (FDA) has accepted for review...
Advertisements
Marea MAR002 Acromegaly Data Set for ENDO 2026
SOUTH SAN FRANCISCO, Calif., May 26, 2026 Marea Therapeutics announced that new data from its first-in-human Phase 1 clinical...
Crinetics Submits Brazil MAA for Palsonify Drug
San Diego, USA – March 26, 2026 Crinetics Pharmaceuticals announced the submission of a Marketing Authorization Application (MAA) to...
FDA Approves Paltusotine as First Oral Therapy for Acromegaly
SAN DIEGO, Sept. 25, 2025 — The U.S. Food and Drug Administration (FDA) has approved PALSONIFY™ (paltusotine) as the...
UK Approves Once-Monthly Octreotide Injection for Acromegaly Care
Lund, Sweden — August 28, 2025 — The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval...
Advertisement
